Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to $15.0 million.

  • BioCorRx's Total Current Liabilities rose 8284.94% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 8284.94%. This contributed to the annual value of $8.2 million for FY2024, which is 2762.16% up from last year.
  • According to the latest figures from Q3 2025, BioCorRx's Total Current Liabilities is $15.0 million, which was up 8284.94% from $14.6 million recorded in Q2 2025.
  • BioCorRx's Total Current Liabilities' 5-year high stood at $15.0 million during Q3 2025, with a 5-year trough of $2.8 million in Q2 2021.
  • In the last 5 years, BioCorRx's Total Current Liabilities had a median value of $5.9 million in 2023 and averaged $6.9 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 2102.63% in 2021, then skyrocketed by 9903.2% in 2025.
  • Quarter analysis of 5 years shows BioCorRx's Total Current Liabilities stood at $4.4 million in 2021, then rose by 22.28% to $5.4 million in 2022, then increased by 19.9% to $6.4 million in 2023, then increased by 27.62% to $8.2 million in 2024, then soared by 83.22% to $15.0 million in 2025.
  • Its Total Current Liabilities was $15.0 million in Q3 2025, compared to $14.6 million in Q2 2025 and $13.4 million in Q1 2025.